Varian Receives FDA "Breakthrough Device Designation" For Embozene(R) Microspheres For Genicular Artery Embolization For Symptomatic Knee Osteoarthritis

PALO ALTO, Calif., Oct. 13, 2021 -- (Healthcare Sales & Marketing Network) -- Varian, a Siemens Healthineers company, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its Embozene... Devices, Interventional, FDA Varian, Embozene, Microspheres, Genicular Artery Embolization, Osteoarthritis

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2047213

Source: HSMN NewsFeed - October 13, 2021 Category: Pharmaceuticals Source Type: news

More News: Food and Drug Administration (FDA) | Marketing | Osteoarthritis | Pharmaceuticals